Emcure’s method spells a altering advertising and marketing playbook for drugmakers in the case of GLP-1s, which transcend docs, just like innovators and well being firms’ method in western markets. Because the generic market opens up subsequent month, specialists anticipate others to make use of related methods to realize a foothold in an intensely aggressive market.
“We anticipate that there will probably be a big portion of utilization which can sort of be by way of a buyer pool by way of going and talking to the physician,” Samit Mehta, government director of operations at Emcure, informed Mint in an interview.
“In that context, (we’re) getting the training on the market, utilizing influencers, and many others. who’ve been by way of related sorts of points,” Mehta stated.
Emcure launched a marketing campaign known as Profitable Over Weight problems in December, partnering with celebrities like M.S. Dhoni and Neha Dhupia, in addition to social media influencer-doctors like Dr Tanaya Narendra (dr cuterus on Instagram) to boost consciousness about weight problems.
The thought is to create a strong affected person assist system, with a helpline, in addition to dietary counselling and utilization steerage, Mehta added.
“What is essential to us is the market-shaping actions which might be taking place by way of educating each the medical fraternity in addition to (customers)… there’s a whole lot of shopper consciousness already for this product,” Vikas Thapar, president of company growth, technique and finance, stated.
Medical doctors and drugmakers have cautioned over misinformation round semaglutide being circulated on social media, and have been making an attempt to realign the dialog.
Forward of the pack
“There’s every kind of misinformation or scaremongering taking place on social media platforms, so it is actually extra about educating the overall inhabitants and the docs about the advantages and security of the product,” Thapar added.
Emcure can also be tapping into its sturdy presence in cardiology, following its partnership with Sanofi for key cardiac manufacturers, to achieve extra docs in that phase.
Poviztra is one other model of Wegovy, which is indicated for weight administration and cardiovascular danger discount.
Emcure has a head begin within the Indian market, which can quickly be inundated with cheaper generics as semaglutide is ready to lose patent exclusivity in March.
Others, like Dr Reddy’s and Solar Pharma, have already obtained regulatory approval and indicated first-day launches.
Poviztra is a semaglutide injection that comes as a once-weekly pen machine in 5 strengths: 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, and a upkeep dose of two.4 mg. The merchandise are priced competitively, beginning at roughly ₹2,200 per week, or ₹8,790 monthly, and rising with the energy of the dosage.
Thapar stated that the entry of generics will solely widen consciousness and entry, and that Emcure will proceed to cost its model competitively.
Specialists consider that the large recognition of weight reduction medication and their notion as life-style medication will reshape the advertising and marketing panorama for drugmakers.
“With GLP-1s, the dimensions of the market is so large, it goes past diabetes…as a result of the indication is weight problems, it has unlocked a brand new market. Generic gamers have understood that this isn’t simply common advertising and marketing,” Sujay Shetty, PwC international well being industries advisory chief, informed Mintincluding that the market development potential for GLP-1s is huge on condition that the drug can also be being thought of for varied different well being indications.
“That is on the intersection of pharma and shopper markets, resulting in the consumerisation of pharma,” he stated.
Dangers of life-style notion
Nevertheless, docs warning towards celeb endorsements, which have up to now fallen squarely throughout the purview of OTC medication in India. “Whereas it would get extra eyeballs, it’s trivialising the science…sufferers might consider that that is only a beauty approach to reduce weight, however it’s a sensible molecule which has advantages method past beauty use,” Dr Rajiv Kovil, Mumbai-based diabetologist, stated.
Medical doctors have additionally cautioned towards the misuse of the drug for purely beauty functions.
Emcure, which was listed on the inventory exchanges in July 2024, posted its third-quarter monetary outcomes on Wednesday. It reported a revenue after tax of ₹231 crore in Q3FY26, up 48.2% year-on-year. Income rose 20.4% YoY to ₹2,363 crore.
The expansion was pushed by sturdy efficiency in each home and worldwide companies.
Its home enterprise grew 15.4%, led by sturdy efficiency throughout all key therapies, particularly power segments comparable to cardio/diabetic, and aided by new initiatives, the corporate stated in a launch.
Worldwide enterprise, in the meantime, grew 24.5% with all geographies reporting double-digit development.